COVID-19 Evidence Network to support Decision-making (COVID-END) - Extension

  • Funded by Canadian Institutes of Health Research (CIHR)
  • Total publications:251 publications

Grant number: Unknown

Grant search

Key facts

  • Disease

    COVID-19
  • start year

    2020
  • Known Financial Commitments (USD)

    $825,000
  • Funder

    Canadian Institutes of Health Research (CIHR)
  • Principal Investigator

    N/A

  • Research Location

    Canada
  • Lead Research Institution

    McMaster University
  • Research Priority Alignment

    N/A
  • Research Category

    Policies for public health, disease control & community resilience

  • Research Subcategory

    Policy research and interventions

  • Special Interest Tags

    N/A

  • Study Type

    Non-Clinical

  • Clinical Trial Details

    N/A

  • Broad Policy Alignment

    Pending

  • Age Group

    Adults (18 and older)

  • Vulnerable Population

    Unspecified

  • Occupations of Interest

    Unspecified

Abstract

The science about how to prevent and manage COVID-19 and its spill-over effects on society is changing rapidly. Summaries of the best available science (which we call evidence syntheses) are the best place to turn when making decisions about public-health measures (e.g., wearing masks), clinical management (e.g., prescribing drugs), health-system arrangements (e.g., making the most of virtual doctor visits), and economic and social responses (e.g., adjusting schools and workplaces). COVID-END will bring together: 1) 25+ Canadian evidence-synthesis teams; 2) leaders of key Canadian initiatives that support the use of science by citizens, service providers and policymakers; 3) diverse citizen partners from across Canada; 4) Canadian professional bodies; and 5) policymakers and leaders from Canadian governments and health authorities. COVID-END will: 1)prepare and update evidence syntheses at the request of Canadian decision-makers in timelines ranging from 4 hours to 10 days; 2)maintain an inventory of the best evidence syntheses for COVID-19 decisions to ensure that Canadian decision-makers have available at all times the most updated summarized science; 3)work with Canadian decision-makers to ensure that their most urgent questions are prioritized and responded to by the most appropriate team in a timely way and that these decision-makers have the capacity to find and use the available science in their decision-making; 4)keep alert to emerging issues where evidence syntheses may be needed in the future; and 5)work with Canadian and global partners to reduce duplication and enhance coordination in the evidence response to COVID-19. COVID-END will undertake (or co-create) its work in close partnership with citizens and with the decision-makers who pose questions and whose existing processes we need to intersect with. COVID-END will disseminate and support the use of its work both directly and through many existing initiatives.

Publicationslinked via Europe PMC

Last Updated:2 hours ago

View all publications at Europe PMC

Developing injury and illness epidemiology and surveillance in cycling (PhD Academy Award).

Effects of Hand-Rearing and Group Size on Chimpanzee (Pan troglodytes) Social Competence in Captivity.

Revisiting Spirituality in Physical Therapy Practice: Perceptions of US Practitioners.

Aflibercept for Wet Age-Related Macular Degeneration: A Prospective, Randomized Trial Comparing Treat-And-Extend and Fixed Bimonthly Dosing.

The Concentration and Duration of Lipopolysaccharide Stimulation Produce Different Cytokine Responses in an Ex Vivo Whole Blood Model in Horses.

History of Shrimp Farming and the Main Viral and Bacterial Diseases in Mexico.

Identification of Risk Factors in Patients with Recurrent Cystitis May Improve Individualized Management.

IS<i>Apl4</i>, a New IS<i>1595</i> Family Insertion Sequence Forming a Novel Pseudo-Compound Transposon That Confers Antimicrobial Multidrug Resistance in <i>Actinobacillus pleuropneumoniae</i>.

Living with Dysphagia and Dysarthria: A Qualitative Exploration of the Perspectives of People with Motor Neuron Disease and Their Caregivers.